| Not Yet Recruiting | A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate NCT06941480 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity NCT06406465 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropa NCT06937905 | Intergroupe Francophone de Cancerologie Thoracique | Phase 3 |
| Recruiting | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT07038096 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) o NCT06889493 | Peter Hosein, MD | Phase 1 |
| Recruiting | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinom NCT06440057 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies NCT06577987 | Circle Pharma | Phase 1 |
| Recruiting | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI NCT06333314 | UNICANCER | Phase 2 |
| Recruiting | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcin NCT06372626 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Clinical Application of the J-PET Scanner Prototype NCT06242119 | Jagiellonian University | — |
| Recruiting | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT05978284 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Unknown | A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carci NCT05747729 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activ NCT05619744 | Hoffmann-La Roche | Phase 1 |
| Unknown | Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms NCT05709171 | Rigshospitalet, Denmark | Phase 2 |
| Terminated | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET NCT05420636 | Fox Chase Cancer Center | Phase 2 |
| Active Not Recruiting | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Car NCT05262556 | Amr Mohamed MD | Phase 1 |
| Unknown | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standa NCT05627427 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Enrolling By Invitation | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients NCT05396118 | Rigshospitalet, Denmark | Phase 2 |
| Active Not Recruiting | Neuroendocrine Tumors - Patient Reported Outcomes NCT05064150 | University of Iowa | — |
| Unknown | Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm NCT05113355 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine C NCT05076786 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC NCT06400654 | European Institute of Oncology | — |
| Active Not Recruiting | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 NCT04524208 | Karsten Gavenis | Phase 2 |
| Active Not Recruiting | Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carc NCT04701307 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinom NCT04705519 | Peking University | Phase 2 |
| Recruiting | Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carci NCT04268121 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Recruiting | Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC NCT06369181 | Fudan University | — |
| Active Not Recruiting | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) NCT04471727 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 / Phase 2 |
| Recruiting | Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) NCT04464122 | University of Roma La Sapienza | — |
| Recruiting | Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic A NCT04325425 | Centre Hospitalier Universitaire Dijon | Phase 2 |
| Withdrawn | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroe NCT03901378 | Ochsner Health System | Phase 2 |
| Completed | Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract NCT04069299 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Completed | Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms NCT03834701 | Catholic University of the Sacred Heart | N/A |
| Active Not Recruiting | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selec NCT03647163 | Vyriad, Inc. | Phase 1 / Phase 2 |
| Completed | Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment NCT03858855 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Diff NCT03591731 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Active Not Recruiting | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advance NCT03728361 | Dwight Owen | Phase 2 |
| Active Not Recruiting | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors NCT03600233 | TaiRx, Inc. | Phase 2 |
| Completed | Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcino NCT03837977 | The Christie NHS Foundation Trust | Phase 2 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Completed | Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors NCT03290079 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Avelumab in G3 NEC NCT03278405 | Sunnybrook Health Sciences Centre | Phase 1 / Phase 2 |
| Unknown | Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma NCT03279614 | Peking University | Phase 2 |
| Active Not Recruiting | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurre NCT03110978 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors NCT03079440 | Asan Medical Center | Phase 2 |
| Unknown | Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma NCT03168607 | Peking University | Phase 2 |
| Terminated | Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Adva NCT03168594 | Peking University | Phase 2 |
| Terminated | CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas NCT03387592 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Active Not Recruiting | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors NCT03074513 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Ca NCT02936323 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Unknown | Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and M NCT02970786 | Rigshospitalet, Denmark | Phase 1 |
| Unknown | The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUK NCT02688894 | Samsung Medical Center | — |
| Unknown | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin NCT02687958 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 |
| Terminated | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-G NCT02315625 | National Cancer Institute (NCI) | Phase 2 |
| Enrolling By Invitation | RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide NCT02270567 | Wren Laboratories LLC | — |
| Completed | Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) NCT02248012 | Haukeland University Hospital | Phase 2 |
| Unknown | An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients wit NCT02236910 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Unknown | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors NCT02038738 | Ochsner Health System | Phase 1 / Phase 2 |
| Unknown | The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables NCT04583605 | Central Hospital, Nancy, France | — |
| Terminated | P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome NCT01886287 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | 68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs) NCT01879657 | Radio Isotope Therapy of America | N/A |
| Completed | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Ca NCT01642251 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers NCT01121939 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer NCT01396382 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma NCT00607113 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma NCT00663429 | Callisto Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinom NCT00388063 | Callisto Pharmaceuticals | Phase 2 |
| Completed | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemo NCT00363051 | Novartis Pharmaceuticals | Phase 2 |
| Completed | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma NCT00113360 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver NCT00019786 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors NCT00004922 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcino NCT00193531 | SCRI Development Innovations, LLC | Phase 2 |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respon NCT00003514 | Burzynski Research Institute | Phase 2 |